Skip to main content
. 2020 Aug 11;12(8):2245. doi: 10.3390/cancers12082245

Table 2.

Baseline patient characteristics.

Characteristic Study Population
(n = 61)
Sensitive Patients
(n = 38)
Resistant Patients
(n = 23)
p-Value
N (%) N (%) N (%)
Sex
Male 40 (65.6%) 32 (84%) 8 (34.8%) <0.001
Female 21 (34.4%) 6 (16%) 15 (65.2%)
Age
<75 43 (70.5%) 26 (68.4%) 17 (73.9%) 0.649
≥75 18 (29.5%) 12 (31.6%) 6 (26.1%)
Mean Age 67.7 66.9
Performance status (ECOG)
0 31 (50.8%) 24 (63.2%) 7 (30.4%) 0.013
1–2 30 (49.2%) 14 (36.8%) 16 (69.6%)
Smoking habit
Never smokers 24 (39.3%) 13 (34.2%) 11 (47.8%) 0.291
Current or former smokers 37 (60.7%) 25 (65.8%) 12 (52.2%)
Tumor side
Right 24 (39.4%) 15 (39.5%) 9 (39.2%)
Left 20 (32.7%) 13 (34.2%) 7 (30.4 %) 0.634
Rectal 16 (26.3%) 10 (26.3%) 6 (26.1%)
Jejunum 1 (1.6%) 0 1 (4.3%)
Number of metastatic sites
1 30 (49.2%) 18 (47.4%) 12 (52.3%) 0.716
≥2 31 (50.8%) 20 (52.6%) 11 (47.7%)
Time to metastases
Synchronous 38 (62.3%) 27 (71.1%) 11 (47.8%) 0.070
Metachronous 23 (37.7%) 11 (28.9%) 12 (52.2%)
Primary resected
Yes 49 (80.3%) 32 (84.2%) 17 (73.9%) 0.327
No 12 (19.7%) 6 (15.8%) 6 (26.1%)
Previous lines of treatment
0 24 (39.3%) 18 (47.4%) 6 (26.1%)
1 32 (52.5%) 17 (44.7%) 15 (65.2%) 0.246
≥2 5 (8.2%) 3 (7.9%) 2 (8.7%)
Type of anti-EGFR
Cetuximab 33 (54.1%) 21 (55.3%) 12 (52.2%) 0.814
Panitumumab 28 (45.9%) 17 (44.7%) 11 (47.8%)
Combination QT
FOLFOX 18 (29.5%) 14 (36.8 %) 4 (17.4%)
Irinotecan scheme 40 (65.6%) 23 (60.6%) 17 (73.9%) 0.192
Monotherapy 3 (4.9%) 1 (2.6 %) 2 (8.7%)
PFS (months) 18.8 4.7
OS (months) 41.2 17.2

Abbreviations: ECOG, Eastern Cooperative Oncology Group; OS, overall survival; PFS, progression-free survival. p-values below 0.05 are highlighted in bold.